tetano
Editor, Senior Moderator
Biology (Basel)
. 2021 Mar 10;10(3):208.
doi: 10.3390/biology10030208.
Determination of the Concentration of IgG against the Spike Receptor-Binding Domain That Predicts the Viral Neutralizing Activity of Convalescent Plasma and Serum against SARS-CoV-2
Llipsy Santiago[SUP] 1 [/SUP], Iratxe Uranga-Murillo[SUP] 1 [/SUP], Maykel Arias[SUP] 2 [/SUP], Andr?s Manuel Gonz?lez-Ram?rez[SUP] 3 [/SUP], Javier Mac?as-Le?n[SUP] 3 [/SUP], Eduardo Moreo[SUP] 4 [/SUP], Sergio Redrado[SUP] 2 [/SUP], Ana Garc?a-Garc?a[SUP] 3 [/SUP], V?ctor Taleb[SUP] 3 [/SUP], Erandi Lira-Navarrete[SUP] 3 [/SUP], Ram?n Hurtado-Guerrero[SUP] 3 5 6 7 [/SUP], Nacho Aguilo[SUP] 4 [/SUP], Maria Del Mar Encabo-Berzosa[SUP] 8 [/SUP], Sandra Hidalgo[SUP] 1 [/SUP], Eva M Galvez[SUP] 2 [/SUP], Ariel Ramirez-Labrada[SUP] 9 [/SUP], Diego de Miguel[SUP] 1 [/SUP], Rafael Benito[SUP] 1 4 10 [/SUP], Patricia Miranda[SUP] 11 [/SUP], Antonio Fern?ndez[SUP] 12 [/SUP], Jos? Mar?a Domingo[SUP] 11 [/SUP], Laura Serrano[SUP] 13 [/SUP], Cristina Yuste[SUP] 13 [/SUP], Sergio Villanueva-Saz[SUP] 14 [/SUP], Jos? Ram?n Pa?o-Pardo[SUP] 1 15 [/SUP], Juli?n Pardo[SUP] 1 4 5 16 [/SUP]
Affiliations
Abstract
Several hundred millions of people have been diagnosed of coronavirus disease 2019 (COVID-19), causing millions of deaths and a high socioeconomic burden. SARS-CoV-2, the causative agent of COVID-19, induces both specific T- and B-cell responses, being antibodies against the virus detected a few days after infection. Passive immunization with hyperimmune plasma from convalescent patients has been proposed as a potentially useful treatment for COVID-19. Using an in-house quantitative ELISA test, we found that plasma from 177 convalescent donors contained IgG antibodies specific to the spike receptor-binding domain (RBD) of SARS-CoV-2, although at very different concentrations which correlated with previous disease severity and gender. Anti-RBD IgG plasma concentrations significantly correlated with the plasma viral neutralizing activity (VN) against SARS-CoV-2 in vitro. Similar results were found using an independent cohort of serum from 168 convalescent health workers. These results validate an in-house RBD IgG ELISA test in a large cohort of COVID-19 convalescent patients and indicate that plasma from all convalescent donors does not contain a high enough amount of anti-SARS-CoV-2-RBD neutralizing IgG to prevent SARS-CoV-2 infection in vitro. The use of quantitative anti-RBD IgG detection systems might help to predict the efficacy of the passive immunization using plasma from patients recovered from SARS-CoV-2.
Keywords: ELISA; IgG; SARS-CoV-2; antibody; convalescent plasma; coronavirus.
. 2021 Mar 10;10(3):208.
doi: 10.3390/biology10030208.
Determination of the Concentration of IgG against the Spike Receptor-Binding Domain That Predicts the Viral Neutralizing Activity of Convalescent Plasma and Serum against SARS-CoV-2
Llipsy Santiago[SUP] 1 [/SUP], Iratxe Uranga-Murillo[SUP] 1 [/SUP], Maykel Arias[SUP] 2 [/SUP], Andr?s Manuel Gonz?lez-Ram?rez[SUP] 3 [/SUP], Javier Mac?as-Le?n[SUP] 3 [/SUP], Eduardo Moreo[SUP] 4 [/SUP], Sergio Redrado[SUP] 2 [/SUP], Ana Garc?a-Garc?a[SUP] 3 [/SUP], V?ctor Taleb[SUP] 3 [/SUP], Erandi Lira-Navarrete[SUP] 3 [/SUP], Ram?n Hurtado-Guerrero[SUP] 3 5 6 7 [/SUP], Nacho Aguilo[SUP] 4 [/SUP], Maria Del Mar Encabo-Berzosa[SUP] 8 [/SUP], Sandra Hidalgo[SUP] 1 [/SUP], Eva M Galvez[SUP] 2 [/SUP], Ariel Ramirez-Labrada[SUP] 9 [/SUP], Diego de Miguel[SUP] 1 [/SUP], Rafael Benito[SUP] 1 4 10 [/SUP], Patricia Miranda[SUP] 11 [/SUP], Antonio Fern?ndez[SUP] 12 [/SUP], Jos? Mar?a Domingo[SUP] 11 [/SUP], Laura Serrano[SUP] 13 [/SUP], Cristina Yuste[SUP] 13 [/SUP], Sergio Villanueva-Saz[SUP] 14 [/SUP], Jos? Ram?n Pa?o-Pardo[SUP] 1 15 [/SUP], Juli?n Pardo[SUP] 1 4 5 16 [/SUP]
Affiliations
- PMID: 33801808
- DOI: 10.3390/biology10030208
Abstract
Several hundred millions of people have been diagnosed of coronavirus disease 2019 (COVID-19), causing millions of deaths and a high socioeconomic burden. SARS-CoV-2, the causative agent of COVID-19, induces both specific T- and B-cell responses, being antibodies against the virus detected a few days after infection. Passive immunization with hyperimmune plasma from convalescent patients has been proposed as a potentially useful treatment for COVID-19. Using an in-house quantitative ELISA test, we found that plasma from 177 convalescent donors contained IgG antibodies specific to the spike receptor-binding domain (RBD) of SARS-CoV-2, although at very different concentrations which correlated with previous disease severity and gender. Anti-RBD IgG plasma concentrations significantly correlated with the plasma viral neutralizing activity (VN) against SARS-CoV-2 in vitro. Similar results were found using an independent cohort of serum from 168 convalescent health workers. These results validate an in-house RBD IgG ELISA test in a large cohort of COVID-19 convalescent patients and indicate that plasma from all convalescent donors does not contain a high enough amount of anti-SARS-CoV-2-RBD neutralizing IgG to prevent SARS-CoV-2 infection in vitro. The use of quantitative anti-RBD IgG detection systems might help to predict the efficacy of the passive immunization using plasma from patients recovered from SARS-CoV-2.
Keywords: ELISA; IgG; SARS-CoV-2; antibody; convalescent plasma; coronavirus.